A PROSPECTIVE STUDY ON EFFECT OF FLUOXETINE ON PRIMARY HEMOSTASIS OF PATIENTS HAVING MAJOR DEPRESSIVE DISORDER

SHRUTHI KS; NARENDRANATH S; SUDHARSHAN CY; SANTOSH KUMAR M; SHASHIKALA GH; DHANYA KUMAR G

doi:10.22159/ajpcr.2022.v15i10.45485

Authors

SHRUTHI KS Department of Pharmacology, JJM Medical College, Davangere, Karnataka, India.
NARENDRANATH S Department of Pharmacology, JJM Medical College, Davangere, Karnataka, India.
SUDHARSHAN CY Department of Pharmacology, JJM Medical College, Davangere, Karnataka, India.
SANTOSH KUMAR M Department of Pharmacology, JJM Medical College, Davangere, Karnataka, India.
SHASHIKALA GH Department of Pharmacology, JJM Medical College, Davangere, Karnataka, India.
DHANYA KUMAR G Department of Pharmacology, JJM Medical College, Davangere, Karnataka, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i10.45485

Keywords:

Fluoxetine, Depression, Bleeding risk, Cardio protection

Abstract

Objectives: The objectives of the study were to study the effect of fluoxetine on bleeding time, clotting time and platelet count of depressed patients.

Methods: Patients diagnosed with major depressive disorder were included in the study to fulfill a sample size of 60. Before starting the treatment with fluoxetine, laboratory tests were done which included bleeding time, clotting time, and platelet count. Patients were requested to return for follow-up after 4 weeks of treatment and the laboratory tests were repeated. All the study end point analysis was analyzed based on per-protocol population. Continuous variables were expressed as mean and standard deviations, paired t-test was used for within group comparison and unpaired t-test was used for between group comparisons. p<0.05 was considered to be significant. For categorical variable, frequency and percentage were calculated. For continuous variable, that is, bleeding time, clotting time, and platelet count, mean and standard deviation were calculated.

Results: At the end of 4 weeks, it was observed that there was a significant increase in bleeding time from 1.35±0.08 min to 1.46±0.08 min**. Similarly, there was a significant increase in clotting time from 3.30±0.15 min to 3.38±0.15 min**. It was also observed that there was a significant decrease in platelet count from 3.07±0.67 lakh cells/cu mm to 2.86±0.63 lakh cells/cu mm**.

Conclusion: Fluoxetine has shown to increase bleeding time, clotting time, and decrease platelet count. Hence, fluoxetine induced risk of bleeding and its cardio protective action has to be considered while individualizing therapy in management of depression.

Downloads

Download data is not yet available.

Author Biography

SANTOSH KUMAR M, Department of Pharmacology, JJM Medical College, Davangere, Karnataka, India.

Assistant Professor, Department of Pharmacology.

References

Golan DE, Tashjian AH Jr., Armstrong EJ, Armstrong AW. Principles of Pharmacology. 3rd ed. New Delhi: Wolters Kluwer; 2012.

De Abajo FJ, Montero D, Rodríguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006;98:304-10.

Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007;9:47-59.

Blakely RD, Berson HE, Fremeau RT Jr.,Caron MG, Peek MM, Prince HK, et al. Cloning and expression of a functional serotonin transporter from rat brain. Nature 1991;7:354:66-70.

Hougardy D, Egberts TC, Van Der Graaf F, Brenninkmeijer VJ, Derijks LJ. Serotonin transporter polymorphism and bleeding time during SSRI therapy. Br J Clin Pharmacol 2008;65:761-6.

Andersohn F, Konzen C, Bronder E, Klimpel A, Garbe E. Citalopram-induced bleeding due to severe thrombocytopenia. Psychosomatics 2009;50:297-8.

Belcher PR, Drake-Holland AJ, Noble IM. Serotonin reuptake inhibitors and cardiovascular disease. Vasc Dis Prev 2005;2:67-76.

Chatterjee RN, Mukherjee SP, Nandi DN. Life events and depression. Indian J Psychiatry 1981;23:333-7.

Grover S, Dutt A, Avasthi A. An overview of Indian research in depression. Indian J Psychiatry 2010;52:S178-88.

Dacie JV, Lewis, SM. Bleeding time-investigation of the hemorrhagic disorders. In: Practical Hematology. 5th ed. Churchill Livingstone: London; 1975. p. 324-5.

Ghai CL. A Textbook of Practical Physiology Haematology. 5th ed. New Delhi: Jaypee Brothers; 1999. p. 84-101.

Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Australian burden of disease study: Measuring the loss of health from diseases, injuries and risk factors. Med J Aust 2000;172:592-6.

Blockmans D, Deckmyn H, Vermylen J. Platelet actuation. Blood Rev 1995;9:143-56.

Saltzman AG, Morse B, Whitman MM, Ivanshchenko Y, Jaye M, Felder S. Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes. Biochem Biophys Res Commun 1991;181:1469-78.

Kendler KS, Thornton LM, Prescott CA. Gender differences in the rates of exposure to stressful life events and sensitivity to their depressogenic effects. Am J Psychiatry 2001;158:587-93.

Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ. Fluoxetine and bleeding in obsessive compulsive disorder. Am J Psychiatry 1991;148:949.

Humphries JE, Wheby MS, VandenBerg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990;114:727-8.

Song HR, Jung YE, Wang HR, Woo YS, Jun TY, Bahk WM. Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients. Psychiatry Clin Neurosci 2012;66:457-59.

Alvarez JC, Gluck N, Arnulf I, Quintin P, Leboyer M, Pecquery R, et al. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: Effects of clomipramine and fluoxetine. Clin Pharmacol Ther 1999;66:617-24.

Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000;68:435-42.

Gomez-Gil E, Gasto C, Carretero M, Díaz-Ricart M, Salamero M, Navinés R, et al. Decrease of the platelet 5-HT2A receptor function by long-term imipramine treatment in endogenous depression. Hum Psychopharmacol 2004;19:251-8.

Cramer SC, Schiller GJ. Acquired abnormalities of platelet function. N Engl J Med 1991;324:1670-2.

Kumar SS, George J, Mukkadan JK, Jasira Mchamed VK. Bleeding time and clotting time in healthy male and female college students of Karukutty Village, Kerala. Health Prospect J Public Health 2013;12:7-9.

Noble MI, Drake-Holland AJ. The possible role of serotonin 5HT2 receptor antagonism in cardioprotection. Neth J Med 1992;41:183-9.

Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation 1999;100:483-9.

Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: A possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001;43:453-62.

Menys VC, Smith CC, Lewins P, Farmer RD, Noble MI. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci (Lond) 1996;91:87-92.

Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000;20:137-40.

Rasmussen A, Hindberg I, Mellerup E. Does sertraline induced platelet dysfunction protect stroke patients against cardiovascular comorbidity. Int J Neuropsychol Pharmacol 2000;3:S372.

Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005;62:792-8.